Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

JDQ443, a Structurally Novel, Pyrazole-Based, Covalent Inhibitor of KRASG12C for the Treatment of Solid Tumors
Edwige Lorthiois, Marc Gerspacher, Kim S. Beyer, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 24, pp. 16173-16203
Closed Access | Times Cited: 65

Showing 1-25 of 65 citing articles:

Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials
Xin Xie, Tingting Yu, Xiang Li, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 144
Expanding Chemical Probe Space: Quality Criteria for Covalent and Degrader Probes
Ingo V. Hartung, Joachim Rudolph, Mary M. Mader, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 14, pp. 9297-9312
Open Access | Times Cited: 56
Recent progress in targeted therapy for non-small cell lung cancer
Yanxia Xiao, Pu Liu, Jie Wei, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 43
Recent advances of anti-angiogenic inhibitors targeting VEGF/VEGFR axis
Lei Wang, Wang‐Qing Liu, Sylvain Broussy, et al.
Frontiers in Pharmacology (2024) Vol. 14
Open Access | Times Cited: 36
Strain-release alkylation of Asp12 enables mutant selective targeting of K-Ras-G12D
Qinheng Zheng, Ziyang Zhang, Keelan Z. Guiley, et al.
Nature Chemical Biology (2024) Vol. 20, Iss. 9, pp. 1114-1122
Open Access | Times Cited: 32
Annual review of KRAS inhibitors in 2022
Hao Wang, Lingling Chi, Fuqiang Yu, et al.
European Journal of Medicinal Chemistry (2023) Vol. 249, pp. 115124-115124
Closed Access | Times Cited: 32
The current landscape of using direct inhibitors to target KRASG12C-mutated NSCLC
Firas Batrash, Mahmoud Kutmah, Jun Zhang
Experimental Hematology and Oncology (2023) Vol. 12, Iss. 1
Open Access | Times Cited: 22
Discovery of MK-1084: An Orally Bioavailable and Low-Dose KRASG12C Inhibitor
Xiaoshen Ma, David L. Sloman, Ruchia Duggal, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 13, pp. 11024-11052
Closed Access | Times Cited: 11
Multiple medicinal chemistry strategies of targeting KRAS: State-of-the art and future directions
Yanguo Shang, Shengnan Fu, Qingjing Hao, et al.
Bioorganic Chemistry (2024) Vol. 144, pp. 107092-107092
Closed Access | Times Cited: 9
MYC and KRAS cooperation: from historical challenges to therapeutic opportunities in cancer
Sílvia Casacuberta‐Serra, Íñigo González-Larreategui, Daniel Capitán-Leo, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 8
Advances in pyrazolo[1,5-a]pyrimidines: synthesis and their role as protein kinase inhibitors in cancer treatment
Terungwa H. Iorkula, Osasere Jude-Kelly Osayawe, Daniel A. Odogwu, et al.
RSC Advances (2025) Vol. 15, Iss. 5, pp. 3756-3828
Open Access | Times Cited: 1
RAS degraders: The new frontier for RAS-driven cancers
Taylor E. Escher, K.J.F. Satchell
Molecular Therapy (2023) Vol. 31, Iss. 7, pp. 1904-1919
Open Access | Times Cited: 19
Targeting KRASG12C in Non-Small-Cell Lung Cancer: Current Standards and Developments
Javier Torres-Jiménez, Javier Baena Espinar, Helena Bote de Cabo, et al.
Drugs (2024) Vol. 84, Iss. 5, pp. 527-548
Closed Access | Times Cited: 6
Second-Generation Atroposelective Synthesis of KRAS G12C Covalent Inhibitor GDC-6036
Jie Xu, Ngiap‐Kie Lim, Jacob C. Timmerman, et al.
Organic Letters (2023) Vol. 25, Iss. 19, pp. 3417-3422
Closed Access | Times Cited: 15
Small molecular inhibitors for KRAS-mutant cancers
Xuan Wu, Wenping Song, Cheng Cheng, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 15
Prognostic and therapeutic impact of the KRAS G12C mutation in colorectal cancer
Lindor Qunaj, Michael May, Alfred I. Neugut, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 14
1‐Azaspiro[3.3]heptane as a Bioisostere of Piperidine**
Alexander A. Kirichok, Hennadii Tkachuk, Yevhenii Kozyriev, et al.
Angewandte Chemie International Edition (2023) Vol. 62, Iss. 51
Open Access | Times Cited: 14
Recent advances in the development of inhibitors targeting KRAS-G12C and its related pathways
Dan Zhao, Yu Liu, Fengchao Yi, et al.
European Journal of Medicinal Chemistry (2023) Vol. 259, pp. 115698-115698
Closed Access | Times Cited: 13
Structural Insights into Small-Molecule KRAS Inhibitors for Targeting KRAS Mutant Cancers
Divya Pandey, Subhash C. Chauhan, Vivek K. Kashyap, et al.
European Journal of Medicinal Chemistry (2024) Vol. 277, pp. 116771-116771
Closed Access | Times Cited: 5
The discovery of novel imidazo[1,2-a]pyridine derivatives as covalent anticancer agents
Qin Song, Qianer Zhang, Xuejing Fan, et al.
Organic & Biomolecular Chemistry (2024) Vol. 22, Iss. 26, pp. 5374-5384
Closed Access | Times Cited: 4
Design, Synthesis and Biological Evaluation of Pyrrolopyrimidine Urea Derivatives as Novel Krasg12c Inhibitors for the Treatment of Cancer
Yongfeng Shang, Shengnan Fu, M. Pang, et al.
(2025)
Closed Access
Discovery of INCB159020, an Orally Bioavailable KRAS G12D Inhibitor
Qinda Ye, Artem Shvartsbart, Zhenwu Li, et al.
Journal of Medicinal Chemistry (2025)
Closed Access
Current Strategies and Future Dimensions in the Development of KRAS Inhibitors for Targeted Anticancer Therapy
Laura D'Alessio‐Sands, Joshua Gaynier, Victoria Michel‐Milian, et al.
Drug Development Research (2025) Vol. 86, Iss. 1
Closed Access
Identification of Structurally Novel KRASG12C Inhibitors through Covalent DNA-Encoded Library Screening
David Huang, Francesco Manoni, Zhen Sun, et al.
Journal of Medicinal Chemistry (2025)
Open Access
Design, synthesis and biological evaluation of pyrrolopyrimidine urea derivatives as novel KRASG12C inhibitors for the treatment of cancer
Yanguo Shang, M. Pang, Shengnan Fu, et al.
European Journal of Medicinal Chemistry (2025) Vol. 289, pp. 117391-117391
Closed Access
Page 1 - Next Page

Scroll to top